These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34816472)

  • 1. Event-specific win ratios for inference with terminal and non-terminal events.
    Yang S; Troendle J; Pak D; Leifer E
    Stat Med; 2022 Mar; 41(7):1225-1241. PubMed ID: 34816472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Event-specific win ratios and testing with terminal and non-terminal events.
    Yang S; Troendle J
    Clin Trials; 2021 Apr; 18(2):180-187. PubMed ID: 33231108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
    Tsujimoto T; Kajio H
    Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial Effects of Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction.
    McDiarmid AK; Swoboda PP; Erhayiem B; Bounford KA; Bijsterveld P; Tyndall K; Fent GJ; Garg P; Dobson LE; Musa TA; Foley JRJ; Witte KK; Kearney MT; Greenwood JP; Plein S
    J Am Heart Assoc; 2020 Jan; 9(1):e011521. PubMed ID: 31852424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
    Tsujimoto T; Kajio H
    J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
    Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
    JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.
    Desai AS; Lewis EF; Li R; Solomon SD; Assmann SF; Boineau R; Clausell N; Diaz R; Fleg JL; Gordeev I; McKinlay S; O'Meara E; Shaburishvili T; Pitt B; Pfeffer MA
    Am Heart J; 2011 Dec; 162(6):966-972.e10. PubMed ID: 22137068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone treatment and clinical outcomes in patients with systolic dysfunction and mild heart failure symptoms: a retrospective analysis.
    Baliga RR; Ranganna P; Pitt B; Koelling TM
    J Card Fail; 2006 May; 12(4):250-6. PubMed ID: 16679256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone for heart failure with preserved ejection fraction.
    Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
    N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
    Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
    Kosmala W; Przewlocka-Kosmala M; Marwick TH
    JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.